3-year follow-up on the 2017 CHAMP study
Key messages
- Clinical improvements reported from the CHAMP study were maintained at three-year follow up.
- There were no differences in headache frequency and disability between individuals taking amitriptyline or topiramate.
- Migraine preventative medication can be stopped in youths with continued good functioning.